SG11201804858YA - Crystalline forms of hydrochloride salts of thienopyrimidine compound - Google Patents
Crystalline forms of hydrochloride salts of thienopyrimidine compoundInfo
- Publication number
- SG11201804858YA SG11201804858YA SG11201804858YA SG11201804858YA SG11201804858YA SG 11201804858Y A SG11201804858Y A SG 11201804858YA SG 11201804858Y A SG11201804858Y A SG 11201804858YA SG 11201804858Y A SG11201804858Y A SG 11201804858YA SG 11201804858Y A SG11201804858Y A SG 11201804858YA
- Authority
- SG
- Singapore
- Prior art keywords
- hwaseong
- gyeonggi
- international
- dongtangiheung
- hee
- Prior art date
Links
- 150000003840 hydrochlorides Chemical class 0.000 title abstract 2
- -1 thienopyrimidine compound Chemical class 0.000 title abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150190853 | 2015-12-31 | ||
| KR20160065977 | 2016-05-27 | ||
| PCT/KR2016/015535 WO2017116192A1 (fr) | 2015-12-31 | 2016-12-30 | Formes cristallines de sels de chlorhydrate d'un composé de thiénopyrimidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804858YA true SG11201804858YA (en) | 2018-07-30 |
Family
ID=59225204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804858YA SG11201804858YA (en) | 2015-12-31 | 2016-12-30 | Crystalline forms of hydrochloride salts of thienopyrimidine compound |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11008333B2 (fr) |
| EP (1) | EP3380481A4 (fr) |
| JP (1) | JP6907439B2 (fr) |
| KR (1) | KR20180089903A (fr) |
| CN (1) | CN108473506B (fr) |
| AU (1) | AU2016382384A1 (fr) |
| BR (1) | BR112018013356A2 (fr) |
| CA (1) | CA3010176A1 (fr) |
| HK (1) | HK1252841A1 (fr) |
| IL (1) | IL259981A (fr) |
| MX (1) | MX2018008006A (fr) |
| PH (1) | PH12018501314A1 (fr) |
| RU (1) | RU2018122050A (fr) |
| SG (1) | SG11201804858YA (fr) |
| TW (1) | TW201726685A (fr) |
| WO (1) | WO2017116192A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200114776A (ko) * | 2019-03-29 | 2020-10-07 | 한미약품 주식회사 | 퓨로피리미딘 화합물의 산 부가염의 결정형 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CN101472930B (zh) | 2006-04-26 | 2011-12-14 | 霍夫曼-拉罗奇有限公司 | 用作PI3K抑制剂的噻吩并[3,2-d]嘧啶的衍生物 |
| US8822500B2 (en) * | 2008-03-19 | 2014-09-02 | Chembridge Corporation | Tyrosine kinase inhibitors |
| DK2975042T3 (en) * | 2010-06-23 | 2019-01-21 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity |
| KR20140118575A (ko) * | 2013-03-29 | 2014-10-08 | 한미약품 주식회사 | 신규한 하이드록사메이트 유도체 |
| WO2015112705A2 (fr) | 2014-01-24 | 2015-07-30 | Clovis Oncology, Inc. | Combinaisons thérapeutiques pour le traitement du cancer |
| TW201622744A (zh) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
| AU2016276963C1 (en) * | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CA3010315A1 (fr) * | 2015-12-31 | 2017-07-06 | Hanmi Pharm. Co., Ltd. | Formes cristallines d'un compose de thienopyrimidine |
-
2016
- 2016-12-30 KR KR1020187018170A patent/KR20180089903A/ko unknown
- 2016-12-30 SG SG11201804858YA patent/SG11201804858YA/en unknown
- 2016-12-30 RU RU2018122050A patent/RU2018122050A/ru not_active Application Discontinuation
- 2016-12-30 JP JP2018533930A patent/JP6907439B2/ja active Active
- 2016-12-30 CN CN201680076606.0A patent/CN108473506B/zh not_active Expired - Fee Related
- 2016-12-30 BR BR112018013356A patent/BR112018013356A2/pt not_active Application Discontinuation
- 2016-12-30 AU AU2016382384A patent/AU2016382384A1/en not_active Abandoned
- 2016-12-30 US US16/066,388 patent/US11008333B2/en active Active
- 2016-12-30 MX MX2018008006A patent/MX2018008006A/es unknown
- 2016-12-30 TW TW105144131A patent/TW201726685A/zh unknown
- 2016-12-30 EP EP16882144.5A patent/EP3380481A4/fr not_active Withdrawn
- 2016-12-30 CA CA3010176A patent/CA3010176A1/fr not_active Abandoned
- 2016-12-30 WO PCT/KR2016/015535 patent/WO2017116192A1/fr active Application Filing
-
2018
- 2018-06-12 IL IL259981A patent/IL259981A/en unknown
- 2018-06-20 PH PH12018501314A patent/PH12018501314A1/en unknown
- 2018-09-20 HK HK18112172.5A patent/HK1252841A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018008006A (es) | 2019-03-14 |
| EP3380481A4 (fr) | 2019-05-15 |
| TW201726685A (zh) | 2017-08-01 |
| US11008333B2 (en) | 2021-05-18 |
| BR112018013356A2 (pt) | 2018-12-04 |
| CN108473506A (zh) | 2018-08-31 |
| RU2018122050A (ru) | 2020-01-31 |
| US20200270268A1 (en) | 2020-08-27 |
| JP6907439B2 (ja) | 2021-07-21 |
| RU2018122050A3 (fr) | 2020-02-28 |
| KR20180089903A (ko) | 2018-08-09 |
| PH12018501314A1 (en) | 2019-02-27 |
| AU2016382384A1 (en) | 2018-07-12 |
| CA3010176A1 (fr) | 2017-07-06 |
| HK1252841A1 (zh) | 2019-06-06 |
| IL259981A (en) | 2018-07-31 |
| WO2017116192A1 (fr) | 2017-07-06 |
| CN108473506B (zh) | 2021-08-17 |
| EP3380481A1 (fr) | 2018-10-03 |
| JP2019500384A (ja) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201810171SA (en) | Kras g12c inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme |